Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 1,901–2,000 of 3,704
Patel, Y. S., & Malvestutto, C. (2024) · Journal of AIDS and HIV Treatment · doi:10.33696/aids.6.047 · Cited by 5
Tirzepatide, a dual incretin analog, is a boon in metabolic syndrome: an editorial
Bardhan, M., Gokhale, P., Roy, P., Kundu, T., & Anand, A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001782 · Cited by 3
“In SURPASS [1,2,5] and SURMOUNT-1 trials [6] and SURPASS J-mono sub-trial [7] , tirzepatide showed a substantial decrease in body weight.”
BackgroundMethodObesity, NAFLD/NASH, and Diabetes
Prattichizzo, F., Ceriello, A., & Shah, V. N. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.2516 · Cited by 5
Conroy, L., McCann, A., Zhang, N., & de Gaetano, M. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00695.2023 · Cited by 5
Putting More Weight on Obesity Trials in Heart Failure
Harrington, J., Sattar, N. A., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Pagidipati, N. J., Pandey, A., Spall, H. G. C. V., & McGuire, D. K. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00655-z · Cited by 3
“Another ongoing cardiovascular outcomes trial is being conducted with tirzepatide, a once-weekly injectable dual GLP-1/GIP receptor agonist with proven efficacy for weight loss [30].”
Weight gain during midlife: Does race/ethnicity influence risk?
Persons, P. A., Williams, L., Fields, H. E., Mishra, S., & Mehta, R. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108013 · Cited by 3
Kasprzyk, P., Wysocka-Konieczna, K., Sobczak, M., & Spychalski, M. I. (2024) · Videosurgery and Other Miniinvasive Techniques · doi:10.5114/wiitm.2024.139687 · Cited by 4
“Glu-cagon-like peptide-1 (GLP-1) receptor agonists and the combination of GLP-1 with glucose-dependent insulinotropic polypeptide (GIP), recently introduced in clinical practice, represent the most effective pharmacotherapy currently available [4, 5].”
BackgroundChartoumpekis, D. V., Chen, I., Salvatore, S. R., Schopfer, F. J., Freeman, B. Α., & Khoo, N. K. H. (2024) · Nitric Oxide · doi:10.1016/j.niox.2024.06.002 · Cited by 4
Advances in the Management of Cardiovascular Disease in the Setting of Human Immunodeficiency Virus
Durstenfeld, M. S., & Hsue, P. Y. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.04.006 · Cited by 3
White, M. E., & Kushnir, V. M. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.003 · Cited by 4
Perioperative Considerations for Patients on GLP1 Agonists
VanderWielen, B. A., & Beam, W. B. (2024) · Advances in Anesthesia · doi:10.1016/j.aan.2024.07.002 · Cited by 3
Ala, M., Jafari, R. M., Dehpour, A. R., & Poursalehian, M. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01621-4 · Cited by 8
“In recently published clinical trials, once-weekly tirzepatide led to a weight loss close to that achieved by bariatric surgery [4, 5, 8].”
A Saudi Heart Association Position Statement on Obesity and Cardiovascular Disease
AlHabeeb, W., Kinsara, A. J., Bakhsh, A., Tash, A. A., Alshammary, A., Almasood, A. S., Alghalayini, K. W., Arafah, M., Hamdy, O., Alsifri, S. N., et al. (2024) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1391 · Cited by 6
“The SURMOUNT-1 trial included patients who are overweight or obese with at least one weight-related comorbidity, excluding diabetes [313].”
BackgroundInfluentialMichalsky, M. P., Fox, C. K., & Pratt, J. S. A. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.10.018 · Cited by 3
Future Medications for Obesity and Clinical Implications
Garvey, W. T. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0004 · Cited by 3
Current status of anti-obesity medications and performance, an EHR based survey
Ruan, X., Li, R., Wang, L., Lu, S., Wen, A., Murali, S. B., & Liu, H. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02423-7 · Cited by 3
Eating- and Weight-Related Disorders in the Armed Forces
Himmerich, H., Gravina, D., Schalinski, I., Willmund, G., Zimmermann, P. L., Keeler, J. L., & Treasure, J. L. (2024) · Metabolites · doi:10.3390/metabo14120667 · Cited by 4
Tirzepatide in Treating Metabolic Disorders
Wei, S., & Xu, S. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100023 · Cited by 4
Talay, L., & Vickers, M. (2024) · Cureus · doi:10.7759/cureus.75603 · Cited by 3
“1 2 Such criticisms cannot be reasonably rebutted with the comparable safety outcomes in the control and intervention groups of GLP-1 RA and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RAs efficacy trials [19,20,21,22], as these studies do not reflect real-world experiences.”
Efficacy of antiobesity medications for weight reduction in older adults: a systematic review
Chen, A. S., Hajduk, A. M., Grimshaw, A. A., Fried, T. R., Jastreboff, A. M., & Lipska, K. J. (2024) · Obesity · doi:10.1002/oby.24160 · Cited by 8
“Clinical trials of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs have shown that adults with diabetes lose less weight than those without diabetes [1, 11, 52].”
InfluentialSelf-citationThe Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment
Louis, M., & Velazquez, E. J. (2025) · Cureus · doi:10.7759/cureus.83903 · Cited by 3
“The recent development and regulatory approval of new classes of pharmacotherapies, particularly glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide and dual incretin receptor agonists such as tirzepatide, represent transformative advancements in medical weight management [9,10].”
Sardà, H., Genua, I., & Miñambres, I. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.106951 · Cited by 6
Dong, J., Starkey, T., Cheng, V. W. T., Clark, J., Pinato, D. J., Robinson, T., Tilby, M., Turnbull, C. D., & Lee, L. Y. W. (2025) · Cancer Epidemiology · doi:10.1016/j.canep.2025.102837 · Cited by 4
Pharmacotherapy in obesity: the current state and the near future
Cho, Y. J., & Kim, K. K. (2022) · Journal of Korean Medical Association · doi:10.5124/jkma.2022.65.8.514 · Cited by 3
Medications for the treatment of obesity
Carette, C., Rives‐Lange, C., & Czernichow, S. (2023) · Journal of Visceral Surgery · doi:10.1016/j.jviscsurg.2022.12.002 · Cited by 5
Behaviour change in the era of biomedical advances
Ali, M. K., Sudharsanan, N., & Thirumurthy, H. (2023) · Nature Human Behaviour · doi:10.1038/s41562-023-01666-x · Cited by 3
Richards, J. R., & Khalsa, S. S. (2023) · doi:10.31234/osf.io/uxa78 · Cited by 3
Radwan, R. M., Lee, Y. A., Kotecha, P., Wright, D. R., Hernandez, I., Ramon, R., Donahoo, W. T., Chen, Y., Allen, J. M., Bian, J., et al. (2025) · medRxiv · doi:10.1101/2025.01.20.25320839 · Cited by 3
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Muraoka, N., Jensen, M. B., Kartha, V. K., Carrico, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.26.678829 · Cited by 3
The Real-World Costs of GLP-1 Receptor Agonist TreatmentPreprint
Wennberg, D. E., Coetzer, H., Marr, A. L., Margiotta, C., Hashmi, R., Kay, J., Vats, V., Hagen, S., Anatale‐Tardiff, L., Rao, S., et al. (2025) · medRxiv · doi:10.1101/2025.10.24.25338255 · Cited by 8
(2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2026-006247 · Cited by 13
Burns, R. B., Jay, M. R., Thorndike, A. N., & Kanjee, Z. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-01740 · Cited by 2
“Recently FDA-approved tirzepa-tide has dual-hormone agonistic activity at the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide receptor (GIP/GLP-1RA) and produces weight loss up to 20% at the highest dose (10 mg subcutaneously) (19, 20).”
(2026) · doi:10.1007/s13668-026-00777-x · Cited by 10
“As a key trial evaluating the efficacy of tirzepatide, SUR-MOUNT-1 (NCT04184622) was consistent with the SUR-PASS studies in demonstrating dose-dependent weight loss [ 66].”
HIV Treatment and Obesity: What’s New?
Freitas, P., & Ribeiro, S. (2024) · Infectious diseases · doi:10.5772/intechopen.112667 · Cited by 2
Osonoi, T., Oura, T., & Hirase, T. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15296 · Cited by 2
Hospitalist Recognition and Treatment of Obesity in Inpatients: A Quality Improvement Cohort Study
Hoppenfeld, M. S., Moss, J. L., & Johnson, S. A. (2024) · Journal of Brown Hospital Medicine · doi:10.56305/001c.94545 · Cited by 2
Dual Agonists for Management of Metabolic Dysfunction–Associated Steatohepatitis
Kanwal, F. (2024) · New England Journal of Medicine · doi:10.1056/nejme2406487 · Cited by 2
Sauter, E. R., & Agurs‐Collins, T. (2024) · Cancers · doi:10.3390/cancers16193275 · Cited by 2
“[29], and tirzapatide led to greater weight loss on average at one year, 19.90% [27], than semaglutide, 15.80% [29].”
BackgroundInfluentialOpalska, L., Muciek, A., Mocarska, M., Orłowska, A., Strakowska, K., Maryńczak, A., Mencel, J., & Nitschke, N. (2024) · Quality in Sport · doi:10.12775/qs.2024.35.56425 · Cited by 4
“The superior results of tirzepatide are likely due to its dual mechanism of action, which enhances insulin secretion via GLP-1 and improves insulin sensitivity via GIP [14].”
InfluentialGanti, A., Tucker, S., Takyi, A. K., Nahid, M., Bickhart, A., Katz‐Feigenbaum, D., & Phillips, E. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70045 · Cited by 2
“…our analysis did not control for the presence of being on a GLP‐1 for the primary treatment of type 2 diabetes and only covers the period from 2012 to 2020 before the release of newer effective incretin‐based therapies, such as Semaglutide and Tirzepatide for the indication of weight loss [33, 37].”
Acute Duodenal Ulcer Perforation Following Tirzepatide Treatment: A Case Report
Hayashi, M., Hayashi, K., Tsujigiwa, Y., Uwafuji, S., Sato, M., & Kobayashi, Y. (2025) · Cureus · doi:10.7759/cureus.80671 · Cited by 2
“In contrast, tirzepatide functions as a dual agonist that targets both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, potentially offering superior weight loss efficacy compared to these other options [2].”
InfluentialRelapse in Anorexia Nervosa Associated With Tirzepatide: A Case Report
Guerdjikova, A. I., Dlugosz, H., Wolterman, R., & McElroy, S. L. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001975 · Cited by 5
Intermuscular Adipose Tissue in CKD: A Window into Muscle Quality and Health?
Demirci, M., Dilaver, R. G., Roshanravan, B., Ikizler, T. A., & Gamboa, J. L. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000745 · Cited by 6
What is the Role of Primary Prevention of Obesity in an Age of Effective Pharmaceuticals?
Gómez‐Martín, M., Canfell, O. J., Chai, L. K., Jansson, A. K., Littlewood, R., Sullivan, C. M., Power, D. D., Clarke, E. D., Ells, L. J., de Vlieger, N., et al. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00632-0 · Cited by 4
“Participants treated with tirzepatide (5, 10, and 15 mg doses) achieved an average WL of up to 20.9%, with the highest dose showing the most pronounced effects [10].”
InfluentialAlali, S., Alotaibi, W. S., Ashodian, K., Achour, N., Almulla, A., & Mutlaq, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1590379 · Cited by 5
Touzot, M., Voican, A., Potier, L., Beaussier, H., Cachanado, M., Sacco, E., Châtellier, G., Ridel, C., Ureña, P., Banu, I., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16484 · Cited by 4
“8 11 (2) Expanding use to non-diabetic obese HD patients as suggested by recent reports from our group and other colleagues with semaglutide.”
Zhao, L., Chen, H., Cheng, Z., Jiang, H., Lu, Y., Xiao, J., Xiao, X., Li, Y., Yuan, Y., & Li, X. (2025) · Obesity · doi:10.1002/oby.24306 · Cited by 3
GERD Management in the Patient with Obesity: Diagnostic and Therapeutic Considerations
Bhatt, A., Ahuja, R. N., & Nguyen, A. D. (2025) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-025-00473-9 · Cited by 4
“The degree of weight loss achieved between anti-obesity medications (AOMs) varies with the GLP-1/GIP receptor agonist, tirzepatide, and GLP-1 receptor agonist, semaglu - tide, having the most pronounced weight loss of all AOMs [69].”
de Zwaan, M., Hauner, H., Holzapfel, C., Engeli, S., Leitlinienkoordinator*in, S. F. A. A., & Adipositas):, V. D. K. T. (. D. Z. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2552-3990 · Cited by 2
Pharmacologic options for the treatment of overweight and obesity
Andrade, M. D. H. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002573 · Cited by 2
Current status, perceptions, and barriers regarding weight loss approaches in China
Lin, Z., Zhu, H., Si, S., Xu, J., Artime, E., Khare, S., Higgins, V., Leith, A., & Bi, Y. (2025) · Endocrine · doi:10.1007/s12020-025-04315-7 · Cited by 5
“…agonist with a weight loss effect of 16.9% at 68 weeks (global data) [19], and tirzepatide, a GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with a weight loss effect of 22.5% at 72 weeks (15 mg; global data) [20], were approved for weight management in China in 2024.”
InfluentialAdverse effects and other aspects of drugs with incretin effect
Ballesteros-Pomar, M. D., & Lesmes, I. B. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107041 · Cited by 4
Association of tirzepatide with erectile dysfunction in people with type 2 diabetes
Cowart, K., Murphy, C., & Carris, N. W. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109116 · Cited by 4
Kang, Z., Jin, Z., Wu, L., Sun, A., Dong, L., Li, J., Li, Q., & Tong, X. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s524000 · Cited by 3
Holmbäck, U. C., Grudén, S., Kuusk, S., Litorp, H., Englund, J., Söderhäll, A., Alderborn, G., & Forslund, A. H. (2025) · Obesity · doi:10.1002/oby.24369 · Cited by 3
“One limitation of the trial is the lack of diversity; almost all participants were White Caucasians, a common problem in many clinical trials [16, 17, 19].”
InfluentialLupus Nephritis: Unmet Needs and Evolving Solutions
Abinti, M., Patricio-Liébana, M., & Anders, H. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000858 · Cited by 3
Birda, C. L., & Sebastian, S. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01854-9 · Cited by 2
“%) even with Tirzepatide 15 mg/week, compared to the previous studies [4, 5].”
InfluentialMolecular Mechanisms Against Successful Weight Loss and Promising Treatment Options in Obesity
Szekeres, Z., Szabados, E., & Pálfi, A. (2025) · Biomedicines · doi:10.3390/biomedicines13081989 · Cited by 4
“These effects are significantly more effective than the standalone GLP-1 receptor agonist effect [105].”
Zohora, F. T., Mou, S. S., Haque, M. R., Baidya, M., Jahan, I., & Al-Mamun, M. E. (2025) · Translational Medicine of Aging · doi:10.1016/j.tma.2025.08.005 · Cited by 2
Increased alcohol intake and alcohol use disorder following bariatric surgery: potential mechanisms
Geliebter, A. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.115094 · Cited by 4
Horn, D. B., Aronne, L. J., Wharton, S., Bays, H. E., Valderas, E. G., Arad, A. D., Sharma, P., Dunn, J. P., Şenyücel, Ç., & Lee, C. J. (2025) · Obesity · doi:10.1002/oby.70014 · Cited by 3
Self-citationLingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
Hedge, E. T., Grappe, S. R., Vernino, S. A., Almandoz, J. P., & Levine, B. D. (2025) · JACC Case Reports · doi:10.1016/j.jaccas.2025.105430 · Cited by 2
Next-Generation Nerve-Sparing Techniques in Robotic Radical Prostatectomy: A Contemporary Review
Piyevsky, B., Gandrabur, A., Bird, P., et al. (2025) · Current Urology Reports · doi:10.1007/s11934-025-01292-2 · Cited by 2
“Recent randomized controlled trials have reported mean body weight reductions of 15–21% over 72 weeks, with the majority of participants achieving clinically significant weight loss [ 33, 34].”
Economic Evaluation of Medications in Prevention and Treatment of Obesity: A Systematic Review
Afshari, S., Khosravi, M., Zamandi, M., Rezapour, A., Hadian, M., Souresrafil, A., Mazaheri, E., & Gallehzan, N. A. (2025) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_368_24 · Cited by 5
“This diversity in both cost and effectiveness profiles underscores the necessity of context‑specific interpretation in economic evaluations of obesity treatments [Table 4].”
Ghazi, L., Dubal, M., Bertoni, A. G., Carson, A. P., Young, B. A., Lewis, C. E., Alanaeme, C. J., Johnson, D. A., Shimbo, D., Foti, K. E., et al. (2025) · Journal of Human Hypertension · doi:10.1038/s41371-025-01078-6 · Cited by 4
“Hypertension is a common metabolic risk factor among United States adults, and its prevalence is a higher among adults with versus without obesity.”
Agarwal, A., & Padwal, R. S. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03745-jc · Cited by 2
Comprehensive Approach to Management of Lipedema
Athavale, A., Fukaya, E., & Aday, A. W. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01126-x · Cited by 3
“In the SUR-MOUNT-1 trial, patients with overweight or obesity treated with tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 agonist, had a dose-dependent 15.0-20.9% weight loss over 72 weeks compared to 3.1% with placebo [45 ].”
InfluentialThermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies
Soliman, S., Andrews‐Dickert, R., Ročić, P., & Mitov, M. I. (2025) · Pharmaceuticals · doi:10.3390/ph18101519 · Cited by 3
“In Lilly’s SURMOUNT-1 trial (international, phase 3, double-blind, randomized, placebo-controlled trial of tirzepatide in persons with obesity), tirzepatide achieved up to a ~21% reduction in body weight over 72 weeks in people with obesity, significantly outperforming placebo [36].”
Byrne, J. P., Hinton, E. C., Humayun, M. A., Pournaras, D. J., Elsworth, R. L., Brunstrom, J. M., Hamilton-Shield, J. P., Sumeray, M. S., Easter, C., & Ashrafian, H. (2025) · Obesity · doi:10.1002/oby.70066 · Cited by 2
Davis, J. P. E., Henry, Z., Sharma, P., Tsunoda, S. M., Han, H., Orandi, B. J., Heimbach, J. K., Schulman, A. R., Tincopa, M. A., Argo, C. K., et al. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.10.008 · Cited by 3
Daniel, E., El-Nayir, M., Ogunniyi, K. E., Patel, Y. B., Olayiwola, P., Oredipe, O., Nwankwo, H., Nwaezeapu, K. I., & Ojo, T. (2025) · Journal of Investigative Medicine · doi:10.1177/10815589251393978 · Cited by 5
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
Ibe, T., & Borlaug, B. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-011141 · Cited by 4
Elbashir, R. M. A., Elbashir, A., Basake, R. U., Mohieldin, A. Z. A., Elhaj, N. A. E., Ebrahim, F. E. M., Ahmed, W. G., & Mahgoub, O. A. M. (2025) · Cureus · doi:10.7759/cureus.95938 · Cited by 3
Li, X., Cao, D., Sapin, H., Wang, F., Hunter, T. M., RAIBULET, N. K., Denning, M., & Kaplan, L. M. (2025) · Obesity · doi:10.1002/oby.70067 · Cited by 4
Fawsitt, C. G., Thom, H. H. Z., Aceituno, D., Jarde, A., Larsen, S., Lübker, C., Kayongo, E., Keeney, E., & FOOS, V. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01555-3 · Cited by 2
“New obesity medications, such as semaglutide 2.4 mg, liraglutide 3.0 mg and tirzepatide (5 mg, 10 mg, 15 mg), are emerging that effectively reduce weight and some of which have demonstrated a reduced incidence of clinical events [19, 20, 35, 36].”
InfluentialComparative analysis of LJ-4378 and tirzepatide in mouse models of obesity and weight regain
Kim, H., Kim, S. W., Choi, C., Joo, S., Kim, G., Kim, M., Yang, E., Lee, J., Chung, S., Jeong, L. S., et al. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01575-9 · Cited by 3
“Clinical studies have reported weight reductions of up to 22.5% over 72 weeks, along with improvements in glycemic control and cardiovascular risk factors (Jastreboff et al. 2022; Sattar et al. 2022).”
InfluentialCardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers
Vetrano, E., Caturano, A., Nilo, D., Lorenzo, G. D., Tagliaferri, G., Piacevole, A., Donnarumma, M., Iadicicco, I., Picco, S., Moretto, S. M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18111703 · Cited by 3
“Superiority was also demonstrated over basal insulin and basal-bolus insulin regimens [68,69].”
Nowak, K., Dziewierz, A., Sojda, A., Zabojszcz, M., Szarpak, Ł., Dardzińska, N., Jaskulska, P., & Siudak, Z. (2025) · Healthcare · doi:10.3390/healthcare13222874 · Cited by 4
“The SURMOUNT series of studies (1–5) showed that tirzepatide led to an average weight loss of − 20.9% at the highest dose of 15 mg ( p 0.001) [2,3].”
InfluentialThe Obesity Drug Revolution: New Frontiers in Pharmacotherapy
Manoria, P. C. (2025) · Cureus · doi:10.7759/cureus.96713 · Cited by 9
“Most of the participants on tirzepatide 15 mg showed body-weight reduction ≥20% and ≥25% at week 72, while serious AEs leading to discontinuation of the drug were mostly associated with tirzepatide 10 mg [52].”
Effects of incretin drugs on glycemic control and body weight
Levitskaya, A. N., Demidova, T. Y., & Геннадьевна, Л. К. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-3-07 · Cited by 2
Sathambihai, T., Mathur, K., & Siddavaram, S. (2025) · Cureus · doi:10.7759/cureus.97410 · Cited by 2
López-Delgado, D. S., Narvaez, C. A., Gonzales, N. D. C., Martinez-Galaviz, R., Rivera‐Lozada, O., & Barboza, J. J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238349 · Cited by 2
“New anti-obesity drugs (e.g., semaglu-tide, tirzepatide) achieve 15–20% weight loss and can reduce cardiovascular events, but they are best used as adjuncts to lifestyle therapy and, in selected cases, to surgery, rather than as stand-alone treatments [46,47].”
Tolvanen, L., Mossberg, K., Grace, L. M., Standen, E. C., Phelan, S. M., Andersson, D. P., & Koball, A. M. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08408-0 · Cited by 2
“…Agonist (GLP-1RA), such as semaglutide and dual-acting GLP-1RA/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist (GIP RA), such as tirzepatide, (hereafter referred to as GLP-1RAs except in participant quotes) have marked a signifi - cant advancement in the treatment of obesity [8 , 9 ].”
Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study
Adam, S., Ibrahim, F. M., Dabou, E. A. R., Pitre, S., Aiman, R., & AbdelSamad, S. (2025) · Healthcare · doi:10.3390/healthcare13233102 · Cited by 4
“Randomized trials demonstrate dose-dependent weight loss (e.g., SURPASS-2 in type 2 diabetes; SURMOUNT-1/3 in obesity), with emerging evidence of greater weight reduction versus semaglutide in some populations [3,4,8].”
Barenbaum, S. R., Aras, M., Kashyap, S. R., & Aronne, L. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf641 · Cited by 2
Self-citationPolisky, M., Kamel, D., & Ku, J.-H. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf290 · Cited by 2
“Although these agents are associated with a lower risk of hypoglycemia compared to other diabetes medications such as sulfonylureas or insulin [2], hypoglycemia remains a re-ported side effect—even in clinical trials involving patients with obesity and no underlying diabetes [3, 4].”
InfluentialBelančić, A., Şener, Y. Z., Vučković, M., Blais, J. E., Fajkić, A., Sher, E. K., Radić, M., & Radić, J. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70378 · Cited by 4
El-hadidy, G. N., Basem, Y., Mokhtar, M. M., Hamed, S. A., Abdelstar, S. M., Nasef, A. R., & Abdelmonem, R. (2025) · Obesities · doi:10.3390/obesities5040086 · Cited by 3
“Mechanistically anchored anti-obesity pharmacotherapy (e.g., semaglutide, tirzepatide) sets new e ffi cacy benchmarks, and the next wave of triple agonists will likely further raise the bar [6,62].”
Galsgaard, K. D., Hartmann, B., ROSENKILDE, M. M., Holst, J. J., Gasbjerg, L. S., & Sørensen, C. M. (2025) · Physiological Reports · doi:10.14814/phy2.70699 · Cited by 3
Liu, L., Chen, J., Zhang, X., Zhu, S., Dai, T., Wu, Q., & Fang, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02064-1 · Cited by 3
Alebna, P. L., Martey, S., Mehta, A., Lavie, C. J., & Carbone, S. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02333-5 · Cited by 3
“These agents have demonstrated impressive weight loss efficacy, achieving average reductions in total body weight of approximately 8%, 16%, and 20% compared to baseline, respectively [46].”
Évolution de la nomenclature des maladies hépatiques stéatosiques : vers un changement de paradigme
Halfon, P. (2025) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2025.12.003 · Cited by 2
Current clinical application of incretin therapy for obesity management
Skinner, K., & Clements, J. N. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0152 · Cited by 5
Genton, L., Sanz, M. L., Arvanitakis, M., Ballesteros-Pomar, M. D., Bally, L., Barazzoni, R., Betry, C., Burgos, R., Cuerda, C., Hadefi, A., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.106550 · Cited by 4
Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size
Turashvili, N. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101452 · Cited by 2
The Future of Obesity Management: Bridging Pharmacologic Innovation and Public Health
Qian, F., & Wang, L. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s579769 · Cited by 2
“9 Evidence from SURMOUNT-CN suggests that tirzepatide, in combination with lifestyle interventions, can produce substantial weight loss, even among individuals at the lower end of the overweight or obesity spectrum.”
Guo, L., Ding, S., Wang, W., Zhang, H., Dai, S., Li, C., Yuan, Y., Stefański, A., Jouravskaya, I., & FORRESTER, T. D. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103722 · Cited by 5
Self-citationLithium toxicity with GLP-1RA co-prescription: clinical considerations and recommendations
Seth, S., & Ramanathan, S. (2025) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2025.100177 · Cited by 4
The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review
Gala, D., Botros, F., & Makaryus, A. N. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm45204 · Cited by 3
“[28–31]).”
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.